Published in J Clin Oncol on August 01, 1997
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol (2008) 3.35
HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res (2006) 2.74
Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol (2000) 2.41
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res (2009) 2.22
Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol (2000) 2.01
Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg (2002) 1.79
Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc Natl Acad Sci U S A (2000) 1.67
Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol (2009) 1.67
Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol (2000) 1.64
Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol (2013) 1.62
Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer (2006) 1.58
Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction. Am J Pathol (2000) 1.55
Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer (2011) 1.47
An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2007) 1.36
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat (2013) 1.34
Breast cancer assessment tools and optimizing adjuvant therapy. Nat Rev Clin Oncol (2010) 1.32
Cause and consequences of genetic and epigenetic alterations in human cancer. Curr Genomics (2008) 1.31
Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res (2009) 1.28
Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Br J Cancer (2017) 1.23
Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Br J Cancer (2009) 1.17
Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Res (2005) 1.17
Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clin Cancer Res (2012) 1.17
Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer (2010) 1.15
Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer (1999) 1.14
Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology (2015) 1.13
Chromosome 2 (2p16) abnormalities in Carney complex tumours. J Med Genet (2003) 1.12
Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer (2006) 1.12
Transforming growth factor-beta and breast cancer: Transforming growth factor-beta/SMAD signaling defects and cancer. Breast Cancer Res (2000) 1.11
Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol (2002) 1.11
Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. J Transl Med (2012) 1.10
Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs (2005) 1.08
Targeting the insulin growth factor receptor 1. Hematol Oncol Clin North Am (2012) 1.07
Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest New Drugs (2005) 1.05
Over-expression of BCAT1, a c-Myc target gene, induces cell proliferation, migration and invasion in nasopharyngeal carcinoma. Mol Cancer (2013) 1.04
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast Cancer Res (2013) 1.03
Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. Int J Clin Oncol (2009) 1.03
IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma. J Clin Pathol (2005) 0.99
Prognosis and outcome of small (<=1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status. Oncologist (2010) 0.99
Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers. Oncotarget (2011) 0.98
Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up. Br J Cancer (1999) 0.98
Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clin Pharmacol Ther (2012) 0.98
The fate of chemoresistance in triple negative breast cancer (TNBC). BBA Clin (2015) 0.94
Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer. Front Oncol (2014) 0.94
Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer. J Mol Histol (2004) 0.94
Feedback activation of STAT3 mediates trastuzumab resistance via upregulation of MUC1 and MUC4 expression. Oncotarget (2014) 0.93
Testing for HER2 in Breast Cancer: A Continuing Evolution. Patholog Res Int (2010) 0.92
Pathobiological features of breast tumours in the State of Kuwait: a comprehensive analysis. J Carcinog (2007) 0.91
HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol (2016) 0.91
Phenotypic and genetic characterization of circulating tumor cells by combining immunomagnetic selection and FICTION techniques. J Histochem Cytochem (2008) 0.90
Detection of circulating tumour cells in patients with breast or ovarian cancer by molecular cytogenetics. Br J Cancer (1999) 0.89
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. Breast Cancer Res (2012) 0.89
c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates. Br J Cancer (1999) 0.89
MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN. BMB Rep (2014) 0.88
Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer. Br J Cancer (2010) 0.88
High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients. J Cancer Res Clin Oncol (2011) 0.88
Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients. Invest New Drugs (2004) 0.88
Lung cancer biomarkers, targeted therapies and clinical assays. Transl Lung Cancer Res (2015) 0.88
Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of Her-2/neu gene amplification. Am J Pathol (2002) 0.87
Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists. J Mol Diagn (2008) 0.87
Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study. Br J Cancer (2010) 0.87
Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma. J Clin Pathol (2005) 0.86
HER2 overexpression a major risk factor for recurrence in pT1a-bN0M0 breast cancer: results from a French regional cohort. Cancer Med (2014) 0.86
Autophagy Protects from Trastuzumab-Induced Cytotoxicity in HER2 Overexpressing Breast Tumor Spheroids. PLoS One (2015) 0.86
Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future? Diagn Pathol (2006) 0.85
The C-neu mammary carcinoma in Oncomice; characterization and monitoring response to treatment with herceptin by magnetic resonance methods. MAGMA (2004) 0.85
Impact of Serum HER2 Levels on Survival and Its Correlation with Clinicopathological Parameters in Women with Breast Cancer. J Breast Cancer (2012) 0.85
The Effect of Cold Ischemia Time and/or Formalin Fixation on Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Results in Breast Carcinoma. Patholog Res Int (2012) 0.85
Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing. Breast Cancer Res (2005) 0.84
Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer. World J Surg Oncol (2009) 0.83
HER2 evaluation and its impact on breast cancer treatment decisions. Public Health Genomics (2011) 0.83
Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer. BMC Clin Pathol (2006) 0.83
External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme. J Clin Pathol (2006) 0.82
Non-invasive proteomics-thinking about personalized breast cancer screening and treatment. EPMA J (2010) 0.82
Utilization of HER2 genetic testing in a multi-institutional observational study. Am J Manag Care (2012) 0.82
The mitochondrial transporter SLC25A43 is frequently deleted and may influence cell proliferation in HER2-positive breast tumors. BMC Cancer (2012) 0.82
Influenza virus-like particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity. Biotechnol Bioeng (2015) 0.81
PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. Clin Cancer Res (2015) 0.81
Targeting HER2 in breast cancer: overview of long-term experience. Int J Womens Health (2010) 0.80
Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer. BMC Cancer (2012) 0.80
Novel therapeutic strategies for malignant salivary gland tumors: lessons learned from breast cancer. Int J Otolaryngol (2011) 0.80
In situ Protein Detection for Companion Diagnostics. Front Oncol (2013) 0.80
Novel luciferase-based reporter system to monitor activation of ErbB2/Her2/neu pathway noninvasively during radiotherapy. Int J Radiat Oncol Biol Phys (2010) 0.79
Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer. Oncologist (2012) 0.79
Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer. Cancer (2012) 0.79
Prognostic significance of HER2 gene amplification according to stage of breast cancer. J Korean Med Sci (2008) 0.79
The transmembrane domain of Neu in a lipid bilayer: molecular dynamics simulations. Eur Biophys J (2004) 0.79
Evaluation of HER-2/neu status in breast cancer specimens using immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay. Indian J Med Res (2012) 0.78
Toward checkmate: biology and breast cancer therapy for the new millennium. Invest New Drugs (1999) 0.78
A three dimensional thermoplastic microfluidic chip for robust cell capture and high resolution imaging. Biomicrofluidics (2014) 0.77
Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer. J Cancer Res Clin Oncol (2013) 0.77
Sensitive fluorescent in situ hybridisation method for the characterisation of breast cancer cells in bone marrow aspirates. Mol Pathol (1999) 0.77
Lymphokine-activated killer cell susceptibility and adhesion molecule expression of multidrug resistant breast carcinoma. Cancer Cell Int (2006) 0.77
Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment. Virchows Arch (2016) 0.76
HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer. Oncoscience (2015) 0.76
Fully automated fluorescent in situ hybridization (FISH) staining and digital analysis of HER2 in breast cancer: a validation study. PLoS One (2015) 0.76
Combating HER2-overexpressing breast cancer through induction of calreticulin exposure by Tras-Permut CrossMab. Oncoimmunology (2015) 0.76
Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients. Breast Cancer (Dove Med Press) (2014) 0.75
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol (1999) 11.78
Magnetic resonance imaging of the lumbar spine in people without back pain. N Engl J Med (1994) 11.46
Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res (1990) 9.85
Ectopic ossification following total hip replacement. Incidence and a method of classification. J Bone Joint Surg Am (1973) 8.60
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med (2011) 7.89
A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J (1998) 7.39
Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res (1988) 7.30
Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol (2000) 6.68
National case-control study of Kaposi's sarcoma and Pneumocystis carinii pneumonia in homosexual men: Part 1. Epidemiologic results. Ann Intern Med (1983) 6.67
The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders. Arch Gen Psychiatry (1998) 6.34
Predictions of biodiversity response to genetically modified herbicide-tolerant crops. Science (2000) 5.98
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Degenerative disk disease: assessment of changes in vertebral body marrow with MR imaging. Radiology (1988) 5.65
Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A (1987) 5.65
Zoonotic tuberculosis due to Mycobacterium bovis in developing countries. Emerg Infect Dis (1998) 5.51
Primary structure and functional expression of a mammalian skeletal muscle sodium channel. Neuron (1989) 5.13
Identification of self peptides bound to purified HLA-B27. Nature (1991) 4.88
Characterization of three RXR genes that mediate the action of 9-cis retinoic acid. Genes Dev (1992) 4.69
The will and the ways: development and validation of an individual-differences measure of hope. J Pers Soc Psychol (1991) 4.55
Value-based pathology: a cost-benefit analysis of the examination of routine and nonroutine tonsil and adenoid specimens. Am J Clin Pathol (1997) 4.51
Expression of cellular oncogenes in human malignancies. Science (1984) 4.48
KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet (1997) 4.46
Differential expression of cellular oncogenes during pre- and postnatal development of the mouse. Nature (1982) 4.44
Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res (1999) 4.26
Messenger RNA for G1 protein of French bean seeds: Cell-free translation and product characterization. Proc Natl Acad Sci U S A (1978) 4.10
A point-source outbreak of campylobacteriosis associated with consumption of raw milk. J Infect Dis (1985) 3.81
Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat (2001) 3.77
Genetically encoded reporters of protein kinase A activity reveal impact of substrate tethering. Proc Natl Acad Sci U S A (2001) 3.77
Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res (2001) 3.70
Immunodeficiency in female sexual partners of men with the acquired immunodeficiency syndrome. N Engl J Med (1983) 3.67
Promotion criteria for clinician-educators in the United States and Canada. A survey of promotion committee chairpersons. JAMA (1997) 3.63
Suicide within 12 months of contact with mental health services: national clinical survey. BMJ (1999) 3.61
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol (2004) 3.56
Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol (2000) 3.56
Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst (2004) 3.51
Identification of the putative transforming protein of the human T-cell leukemia viruses HTLV-I and HTLV-II. Science (1984) 3.39
MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res (1997) 3.38
Transforming growth factor production by chemically transformed cells. Cancer Res (1981) 3.36
Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis (1997) 3.35
Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene (1996) 3.33
Correction for partial volume effects in PET: principle and validation. J Nucl Med (1998) 3.27
Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer (1991) 3.14
Aetiology of suppurative corneal ulcers in Ghana and south India, and epidemiology of fungal keratitis. Br J Ophthalmol (2002) 3.13
Imaging of degenerative disk disease. Radiology (1988) 3.09
Xenograft model of progressive human proliferative breast disease. J Natl Cancer Inst (1993) 3.03
Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res (1994) 3.03
Childhood leukemia and parents' occupational and home exposures. J Natl Cancer Inst (1987) 3.03
Epidemiology and prevention of breast cancer. Annu Rev Public Health (1996) 2.94
A randomised controlled trial of hospice care. Lancet (1984) 2.93
A carcinogenic potency database of the standardized results of animal bioassays. Environ Health Perspect (1984) 2.92
Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res (1988) 2.90
HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene (1995) 2.84
Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis (1996) 2.84
Gender differences in social desirability and social approval bias in dietary self-report. Am J Epidemiol (1997) 2.83
Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet (1999) 2.83
No change in health risk behaviors over time among HIV infected adolescents in care: role of psychological distress. J Adolesc Health (2001) 2.73
Prognostic classification of breast ductal carcinoma-in-situ. Lancet (1995) 2.70
Immune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data. Genes Immun (2005) 2.69
Cell culture of human colon adenomas and carcinomas. Cancer Res (1987) 2.68
Spatial and temporal variation in malaria transmission in a low endemicity area in northern Tanzania. Malar J (2006) 2.65
Surgical audit in a district general hospital: a stimulus for improving patient care. Ann R Coll Surg Engl (1987) 2.64
Intravenous drug abusers and the acquired immunodeficiency syndrome (AIDS). Demographic, drug use, and needle-sharing patterns. Arch Intern Med (1985) 2.62
MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol (1996) 2.62
BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science (1999) 2.54
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene (1990) 2.50
The x gene is essential for HTLV replication. Science (1985) 2.44
Stage and delay in breast cancer diagnosis by race, socioeconomic status, age and year. Br J Cancer (1992) 2.40
Hedgehog patterning activity: role of a lipophilic modification mediated by the carboxy-terminal autoprocessing domain. Cell (1996) 2.39
Rapid and sensitive quantification of Borrelia burgdorferi-infected mouse tissues by continuous fluorescent monitoring of PCR. J Clin Microbiol (1999) 2.39
Adenoid cystic carcinoma of the head and neck: predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg (1999) 2.35
Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med (1992) 2.34
Nuclear trafficking of Cubitus interruptus in the transcriptional regulation of Hedgehog target gene expression. Cell (1999) 2.34
Benzo(a)pyrene diol epoxides as intermediates in nucleic acid binding in vitro and in vivo. Science (1976) 2.34
Genome comparisons reveal a dominant mechanism of chromosome number reduction in grasses and accelerated genome evolution in Triticeae. Proc Natl Acad Sci U S A (2009) 2.32
Seroprevalence and epidemiological correlates of HTLV-I infection in U.S. blood donors. Science (1988) 2.31
A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control (2001) 2.31
Acquired immunodeficiency with reversed T4/T8 ratios in infants born to promiscuous and drug-addicted mothers. JAMA (1983) 2.29
Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst (1986) 2.27
Telecytology: diagnostic accuracy in cervical-vaginal smears. Am J Clin Pathol (1996) 2.26
Susceptibility of Fanconi's anaemia fibroblasts to chromosome damage by carcinogens. Nature (1976) 2.24
The completeness of AIDS case reporting in New York City. JAMA (1993) 2.20
Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J Natl Cancer Inst (1998) 2.19
The Goldman algorithm revisited: prospective evaluation of a computer-derived algorithm versus unaided physician judgment in suspected acute myocardial infarction. Am Heart J (1999) 2.19
Definitive identification of mammalian 5-hydroxymethyluracil DNA N-glycosylase activity as SMUG1. J Biol Chem (2001) 2.19
Job activity and colon cancer risk. Am J Epidemiol (1984) 2.15
Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A (1999) 2.14
Transcription of c-onc genes c-rasKi and c-fms during mouse development. Mol Cell Biol (1983) 2.14
Residential radon gas exposure and lung cancer: the Iowa Radon Lung Cancer Study. Am J Epidemiol (2000) 2.13
Hyperintense disks on T1-weighted MR images: correlation with calcification. Radiology (1995) 2.13
Enzyme activities associated with maize kernel amyloplasts. Plant Physiol (1988) 2.12
Atypical glandular cells of undetermined significance. Diagnostic accuracy and interobserver variability using select cytologic criteria. Am J Clin Pathol (1997) 2.12
Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol (2001) 2.11
Studies of the human c-myb gene and its product in human acute leukemias. Science (1986) 2.10
The severity of circulating neutrophil dysfunction in patients with cirrhosis is associated with 90-day and 1-year mortality. Aliment Pharmacol Ther (2014) 2.10
Intravenous sedation for MR imaging of the brain and spine in children: pentobarbital versus propofol. Radiology (1993) 2.09